Categories AlphaGraphs, Analysis, Earnings, Retail
Earnings preview: Higher meat demand could benefit Tyson Foods’ Q3 results
Tyson Foods Inc. (NYSE: TSN) is scheduled to report third quarter 2019 earnings results on Monday, August 5, before market open. Analysts have forecast earnings of $1.43 per share on revenue of $11.05 billion.
The chicken and beef businesses are likely to benefit from higher meat prices as well as strong supply and demand dynamics. This could help cushion the impact to the company from higher feed costs and weak demand in the pork segment. In addition, a reduction in pork supply due to African Swine Fever could benefit Tyson’s chicken, beef and pork businesses.
The Prepared Foods business is a key growth driver for the company and currently generates 30% of its profits. Tyson is seeing strong demand for proteins alongside a growing preference for plant-based protein products. To take advantage of this trend, the company has rolled out its own plant-based and blended products along with its Raised and Rooted brand.
The alternative protein market is estimated to be a multi-billion dollar category in the future and Tyson is looking to grow its footprint in this space.
During the quarter, Tyson completed the acquisition of the Thai and European operations of BRF S.A., which will help the company expand its offerings in the traditional protein market. Around 98% of protein consumption growth is estimated to happen outside the US over the next five years, and approx. 70% of this growth will be in Asia. The acquisitions of Keystone and the BRF assets can be expected to benefit Tyson’s topline numbers in the quarter.
In the second quarter of 2019, Tyson beat market estimates for revenue and earnings. Sales grew 7% to $10.4 billion while adjusted EPS fell 6% to $1.20. For full-year 2019, the company has guided for adjusted EPS of $5.75-6.10.
Tyson’s shares have gained 55% year-to-date and 8% over the past three months. The majority of analysts have rated the stock Buy and the average 12-month price target is $87.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on